^
    Back
    Association details:
    Biomarker:PAX5 overexpression
    Cancer:Prostate Cancer
    Drug:Zejula (niraparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

    Published date:
    11/02/2022
    Excerpt:
    Thirty patients were treated with niraparib and radium-223...Whole blood gene expression of PAX5 and CD19 were higher in responders and ARG-1, IL-2R and FLT3 expression were higher in non-responders.
    Secondary therapy:
    radium Ra-223 dichloride
    DOI:
    10.1158/1078-0432.CCR-22-2526